Camelot Portfolios’s Adient ADNT Stock Holding History

Camelot Portfolios’s Portfolio ADNT Stock Details ADNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,971	Closed	-$153K	–	197
2025 Q4	$153K	Buy	+7,971	New	+$168K	0.09%	204

Other funds holding ADNT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Camelot Portfolios's ADNT Position: Q1 2026 in Review

Camelot Portfolios sold out of Adient (ADNT) in Q1 2026, closing a stake of 7,971 shares — an estimated $153K sold.

Camelot Portfolios first reported a position in ADNT in Q4 2025 and held it in 1 quarter. The position peaked at $153K in Q4 2025. 291 funds tracked by Wall St. Rank hold ADNT as of Q1 2026.

Camelot Portfolios reported no remaining Adient position as of Q1 2026 after selling out during the quarter.
Camelot Portfolios sold 7,971 Adient shares in Q1 2026, an estimated $153K.
Camelot Portfolios first reported a position in Adient in Q4 2025 and held it in 1 quarter.
Camelot Portfolios's Adient position peaked at $153K in Q4 2025.
291 funds tracked by Wall St. Rank held Adient as of Q1 2026.

Based on Camelot Portfolios's 13F filing for Q1 2026, filed 8 May 2026.